Trazodone associated with Clomiphene a proposal treatment for post finasteride syndrome
Department of biochemistry institute of chemistry, University of São Paulo, Av. Prof. Lineu Prestes, 748, Sao Paulo, 05508-900, Brazil.
Review Article
Magna Scientia Advanced Research and Reviews, 2023, 09(02), 147–149
Article DOI: 10.30574/msarr.2023.9.2.0167
Publication history:
Received on 02 November 2023; revised on 11 December 2023; accepted on 14 December 2023
Abstract:
Erectile dysfunction caused by medications are probably caused by the disconnection of synaptic circuits responsible for linking libido to erection. For instance, it is well known that sexual dysfunction may occur in patients treated with finasteride, an inhibitor of the enzyme 5alpha-reductase, prescribed for androgenetic alopecia and benign prostatic hyperplasia. Interestingly, sexual dysfunction persists after drug discontinuation. Clomiphene citrate is a selective estrogen receptor modulator that has been used for the treatment of hypogonadism in men. It acts centrally to increase secretion of luteinizing hormone. Trazodone is a multifunctional drug with hypnotic actions at low doses due to blockade of 5-HT2A receptors, as well as H1 histamine receptors and α1 adrenergic receptors, therefore this drug can cause severe priapism and in many cases causing penile necrosis or permanent loss of erectile function. Therefore, we propose that trazodone and clomiphene can restore libido synaptic circuits, thus these associated drugs can be a treatment for post-finasteride syndrome.
Keywords:
Trazodone treatment; Clomiphene treatment; Post finasteride syndrome; Epigenetic mechanism
Full text article in PDF:
Copyright information:
Copyright © 2023 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0